220 related articles for article (PubMed ID: 12670352)
1. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Mourad FH; Hoffbrand AV; Sheikh-Taha M; Koussa S; Khoriaty AI; Taher A
Br J Haematol; 2003 Apr; 121(1):187-9. PubMed ID: 12670352
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
3. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with deferiprone and desferrioxamine.
Wonke B; Wright C; Hoffbrand AV
Br J Haematol; 1998 Nov; 103(2):361-4. PubMed ID: 9827905
[TBL] [Abstract][Full Text] [Related]
5. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
[TBL] [Abstract][Full Text] [Related]
7. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Aydinok Y; Evans P; Manz CY; Porter JB
Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
[TBL] [Abstract][Full Text] [Related]
8. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
10. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
[TBL] [Abstract][Full Text] [Related]
12. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
15. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
[TBL] [Abstract][Full Text] [Related]
17. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Mirbehbahani N; Jahazi A; Rahim Abad HH
Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
Parakh N; Chandra J; Sharma S; Dhingra B; Jain R; Mahto D
J Pediatr Hematol Oncol; 2017 Apr; 39(3):209-213. PubMed ID: 28221264
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
20. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Peng CT; Chow KC; Chen JH; Chiang YP; Lin TY; Tsai CH
Eur J Haematol; 2003 Jun; 70(6):392-7. PubMed ID: 12756022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
